4.7 Article

Management of Pulmonary Arterial Hypertension

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 65, Issue 18, Pages 1976-1997

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.03.540

Keywords

echocardiography; endothelin receptor antagonists; hemodynamics; phosphodiesterase type 5 inhibitors; prostacyclins; pulmonary arterial hypertension

Funding

  1. Actelion Bayer
  2. Gilead
  3. United Therapeutics
  4. Actelion
  5. Bayer
  6. National Institutes of Health [R24 HL123767, R01 HL107577]
  7. Actelion Pharmaceuticals
  8. American Board of Internal Medicine
  9. Novartis
  10. DC Devices
  11. AstraZeneca
  12. Alnylam Pharmaceuticals
  13. Pulmonary Hypertension Association
  14. American Society of Echocardiography
  15. GlaxoSmithKline
  16. Bristol-Myers Squibb

Ask authors/readers for more resources

Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by progressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH. Cardiac studies, including echocardiography and right heart catheterization, are key elements in the assessment. Given the multitude of treatment options currently available for PAH, assessment of risk and response to therapy is critical in long-term management. This review also underscores unique situations, including perioperative management, intensive care unit management, and pregnancy, and highlights the importance of collaborative care of the PAH patient through a multidisciplinary approach. (C) 2015 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available